Entero Therapeutics (NASDAQ:ENTO) Stock Price Up 22.8% – Here’s What Happened
by Teresa Graham · The Cerbat GemEntero Therapeutics, Inc. (NASDAQ:ENTO – Get Free Report)’s stock price shot up 22.8% during mid-day trading on Thursday . The stock traded as high as $2.63 and last traded at $2.48. 235,729 shares were traded during mid-day trading, an increase of 86% from the average session volume of 126,532 shares. The stock had previously closed at $2.02.
Entero Therapeutics Stock Down 3.6%
The business has a fifty day moving average of $2.59 and a 200 day moving average of $3.39. The firm has a market cap of $3.80 million, a P/E ratio of -1.41 and a beta of 1.19.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC bought a new position in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned 0.74% of Entero Therapeutics at the end of the most recent reporting period. Institutional investors own 12.30% of the company’s stock.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.
Entero’s pipeline features multiple lead candidates in varying stages of clinical development.